Micro-hematology Analyzer for Viral/Bacterial Description

Sponsor
RizLab Health, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05090319
Collaborator
Baylor College of Medicine (Other)
200
1
12
16.7

Study Details

Study Description

Brief Summary

The purpose of the study is to evaluate the reliability and accuracy of a newly developed point-of-care analyzer, theCytoTracker, to measure complete blood count (CBC) parameters and discriminate between viral and bacterial infections.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: complete blood count

Detailed Description

The purpose of the study is to evaluate the reliability and accuracy of a newly developed point-of-care analyzer, the CytoTracker, to measure complete blood count (CBC) parameters. The CytoTracker results will be compared to those from a standard benchtop analyzer (Horiba Point of Care Hematology Analyzer, ABX Micros ES 60). If successful, the data from this study would be used to support a pre-submission meeting to the FDA for the CytoTracker. In addition to validating the CytoTracker, the project will study the use of CBC parameters to distinguish between observed bacterial or viral infections in adults. Hospitalized adult subjects with suspected or confirmed viral or bacterial infections will be enrolled in the study. After enrollment a venous blood sample (baseline sample) will be collected and the CytoTracker will be used to measure CBC parameters (cell counts and population distribution). Clinical data will be abstracted from the medical record and used with the CBC parameters to develop an algorithm to distinguish between bacterial and viral infections.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Use of a Micro-hematology Analyzer for Discriminating Between Viral and Bacterial Infections in Hospitalized Adults: An Observational Study
Actual Study Start Date :
Jul 25, 2021
Anticipated Primary Completion Date :
Jul 24, 2022
Anticipated Study Completion Date :
Jul 24, 2022

Arms and Interventions

Arm Intervention/Treatment
Viral Group

known viral infection

Diagnostic Test: complete blood count
Complete blood count will be performed on the patient. Accuracy of micro-hematology analyzer will be assessed.

Bacterial group

known bacterial infection

Diagnostic Test: complete blood count
Complete blood count will be performed on the patient. Accuracy of micro-hematology analyzer will be assessed.

Outcome Measures

Primary Outcome Measures

  1. Accuracy [1 year]

    Accuracy of Device in quantifying WBC, Neutrophils, and Lymphocytes; Accuracy of Viral/Bacterial Descrimination

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 64 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

-COVID positive or suspected/confirmed bacterial infection (lower UTI, pneumonia, septecemia, etc). -Adults 18 years of age and older. -Meet SIRS criteria anytime during the ED presentation.

Exclusion Criteria:
  • Subjects who are unable to give informed consent will be excluded

  • Subjects with the following conditions will also be excluded: Known white blood cell, neutrophil, and lymphocyte disorders Active cancer patients; For solid tumors, subject will be excluded if he/she has received chemotherapy in the last 3 months.

  • Subjects who are pregnant

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ben Taub Hospital Houston Texas United States 77030

Sponsors and Collaborators

  • RizLab Health, Inc.
  • Baylor College of Medicine

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
RizLab Health, Inc.
ClinicalTrials.gov Identifier:
NCT05090319
Other Study ID Numbers:
  • H-49795
First Posted:
Oct 22, 2021
Last Update Posted:
Nov 3, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 3, 2021